Neoadjuvant Therapy Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
Conditions: Bladder Cancer; Muscle-Invasive Bladder Carcinoma Interventions: Drug: DisitamabVedotinForIicction Toripalimab Sponsors: Zhujiang Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials

Investigator Grant (IG) 2022 27746
Conditions: Bladder Cancer Interventions: Drug: various neoadjuvant therapies Sponsors: IRCCS San Raffaele Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials

SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER Positive/HER2 Low Breast Cancer
Conditions: ER Positive/HER2 Low Breast Cancer Interventions: Drug: SHR-A1811 Injection + Adebrelimab Injection; Drug: SHR-A1811 Injection + Adebrelimab Injection; Drug: SHR-A1811 Injection Sponsors: Shengjing Hospital; Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials

ICG vs Blue Patent as a Tracer in the Performance of TAD in Patients With cN1 Breast Carcinoma After Neoadjuvant Chemotherapy
Conditions: Breast Cancer; Axillary Metastases Interventions: Procedure: Targeted axillary dissection (TAD) by ICG; Procedure: Targeted axillary dissection (TAD) by Blue patent Sponsors: Hospital Universitari de Bellvitge Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials

PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer
Conditions: Metastatic Colon Cancer Interventions: Drug: Serplulimab, mFOLFOX6 Sponsors: Henan Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials

The Therapeutic Efficacy of 18F-FDG Combined With 18F-FAPI PET/MR in Neoadjuvant Therapy for Gastric Cancer
Conditions: Cancer Interventions: Diagnostic Test: 18F-FAPI#18F-FDG Sponsors: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials

Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer
Conditions: Muscle-Invasive Bladder Carcinoma Interventions: Combination Product: neoadjuvant chemotherapy Sponsors: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2024 Category: Research Source Type: clinical trials

Survival Benefit of Primary Tumour Resection Compared to Systemic Therapy Alone in Stage IV Colorectal Cancer Patients
Conditions: Colorectal Cancer; Neoadjuvant Systemic Therapy Interventions: Procedure: Primary tumor resection; Procedure: Systemic Therapy Sponsors: Medizinische Hochschule Brandenburg Theodor Fontane; Clinical-Epidemiological Cancer Registry Brandenburg-Berlin Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2024 Category: Research Source Type: clinical trials

AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Conditions: Pancreatic Ductal Adenocarcinoma Interventions: Other: Blood sample Sponsors: Roswell Park Cancer Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials

PET/MR Evaluation of Regression Grading After Neoadjuvant Therapy for Rectal Cancer
Conditions: Rectal Cancer Interventions: Diagnostic Test: 18F-FAPI ，18F-FDG Sponsors: Xiao Chen Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials

Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy
Conditions: NSCLC Interventions: Drug: Neoadjuvant immunotherapy; Drug: Other drugs for neoadjuvant treatment Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
Conditions: Stage 1 cT1b-T1cN0M0; Triple Negative Breast Cancer Interventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: Pembrolizumab; Drug: Doxorubicin; Drug: Cyclophosphamide Sponsors: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials

Assessment of Efficacy of Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Conditions: Locally Advanced Rectal Carcinoma Sponsors: Sixth Affiliated Hospital, Sun Yat-sen University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials

Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.
Conditions: HCC Interventions: Drug: HAIC + Tirelizumab +lenvatinib +liver resection; Procedure: liver resection Sponsors: Chen Xiaoping Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials

A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study
Conditions: Locally Advanced Rectal Carcinoma Interventions: Drug: Tislelizumab Sponsors: Beijing Friendship Hospital; Beijing Chao Yang Hospital; Peking University Cancer Hospital& Institute; CHINA-JAPEN FRIENDSHIP HOSPITAL; Peking Union Medical College Hospital; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Fudan University; Changhai Hospital; RenJi Hospital; Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of Medicine; Shandong Provincial Hospital; Zhongnan Hospital of Wuhan University& Second Clinical Hospital of Wuhan University; The First Affiliated Hospital of Zhengzhou...
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials